Published by
@ShahidNShah
@ShahidNShah
April 23 to April 25, 2024
Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States
The 12th Alzheimer's and Parkinson's Drug Development Summit, scheduled from April 23-25, 2024, highlights a resurgence in neurodegenerative drug approvals. Notably, Lecanemab's FDA and PMDA endorsements for a 30% cognitive decline reduction signify a breakthrough. Concurrently, Eli Lilly's Donanemab awaits approval, with 58 trials entering the pipeline. The game-changing alpha-synuclein self-seeding assay in PD drug development marks a paradigm shift. This industry-centric summit presents unpublished AD and PD research by esteemed biopharma KOLs. With comprehensive content spanning early discovery to late-stage trials, 150+ leaders from renowned organizations convene to share insights from preclinical to commercial realms.
[Read on alzheimers-parkinsons](https://alzheimers-parkinsons-summit.com/)
Continue reading at alzheimers-parkinsons-summit.com
April 25 to April 29, 2024
The Colonnade Hotel, 120 Huntington Avenue, Boston, Massachusetts, 02116, United States
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Nov 21, 2024 at 6:20am